Daniel Wagner

Senior Managing Director, Investments at Connecticut Innovations, Inc.

Daniel Wagner

Daniel Wagner

Senior Managing Director, Investments at Connecticut Innovations, Inc.

Overview
RelSci Relationships

645

Number of Boards

2

Contact Data
Trying to get in touch with Daniel Wagner? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Daniel Wagner likely has professional access to. A relationship does not necessarily indicate a personal connection.

Venture Partner at LaunchCapital LLC

Relationship likelihood: Strong

Founder at New Haven Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer at CMDBioscience, Inc.

Relationship likelihood: Strong

President, Chief Executive Officer, Secretary & Director at Innovatient Solutions, Inc.

Relationship likelihood: Strong

Chief Executive Officer at MyCare, Inc.

Relationship likelihood: Strong

Co-Founder, Director at IsoPlexis Corp.

Relationship likelihood: Strong

President, Chief Executive Officer & Director at New Haven Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Operating Officer, Secretary & Treasurer at CMDBioscience, Inc.

Relationship likelihood: Strong

Former Chief Executive Officer, Co-Founder at IsoPlexis Corp.

Relationship likelihood: Strong

Chief Executive Officer, Founder at EpiEp, Inc.

Relationship likelihood: Strong

Paths to Daniel Wagner
Potential Connections via
Relationship Science
You
Daniel Wagner
Senior Managing Director, Investments at Connecticut Innovations, Inc.
Education
BS Biology

The University of Dayton (UD) is a private Roman Catholic national research university in Dayton, Ohio, United States. Founded in 1850 by the Society of Mary, it is one of three Marianist universities in the nation and the largest private university in Ohio. The university's campus is located in the southern portion of the city of Dayton and spans 388 acres on both sides of the Great Miami River.

Master of Business Administration

Quinnipiac is a private, coeducational university with 6,200 undergraduate and 2,300 graduate students. Quinnipiac is consistently ranked among the best universities by U.S. News & World Report.

Career History
Senior Managing Director, Investments
2007 - Current

CI typically invests between $500,000 and $1,000,000 per round into our companies. Our focus in on building technology and technology-enabled enterprises in Connecticut, in industries where Connecticut has a strong position and competitive advantage. To date, primarily invested in software and IT, bioscience, clean tech, digital media and technologies important to advanced manufacturing such as photonics and advanced materials. We actively seek pre-seed, seed and early stage (Series A) investments.We look for components of the following three characteristics in evaluating investment opportunities, each of which we believe are necessary to build extraordinary companies:ManagementMarketTechnologyCI accomplishes their mission primarily by making equity investments in emerging Connecticut technology companies, providing essential, non-financial support to entrepreneurs and conducting initiatives that address specific needs of Connecticut's technology sector

Professional
Prior

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.

Boards & Committees
Director
Current

IsoPlexis Corp. develops a single cell multiplexing immunoassay and software. Its tool enables discovery of novel biomarkers and accurate testing of molecules for clinical activity against heterogeneous subsets. The company was founded by Sean Mackay, Rong Fan, and Kara K. Brower in 2012 and is headquartered in Branford, CT.

Director
Current

New Haven Pharmaceuticals, Inc. develops new prescription drug products. It developes proprietary prescription pharmaceuticals that utilize currently marketed drugs or generally recognized as safe (GRAS) active pharmaceutical ingredients (APIs) for use in therapeutic applications. The company was founded by Harry H. Penner Jr. in 2008 and is headquartered in Branford, CT.

Director
Current

BioRez, Inc. engages in the design and development of resorbable polymer scaffold technology. The firm offers a device that is suited for tendon, ligament, and other soft tissue injuries. The company was founded by Cato T. Laurencin and Joseph W. Reilly in 2008 and is headquartered in New Haven, CT.

Board Member
Current

Crossroads Venture Group, Inc. provides investment advisory services. The firm assists in the development of growth enterprises through the promotion of capital formation in Connecticut. The company is headquartered in East Hartford, CT.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Daniel Wagner. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Daniel Wagner's profile does not indicate a business or promotional relationship of any kind between RelSci and Daniel Wagner.